Table 1.

Summary of recommendations for COVID-19 screening during fertility treatment by national/international scientific reproductive medicine societies

	European Society of Human Reproduction and Embryology (ESHRE)	American Society for Reproductive Medicine (ASRM)	British Fertility Society/Association of Reproductive and Clinical Scientists (BFS/ARCS)	Canadian Fertility and Andrology Society (CFAS)
Risk triage by self-assessment	Yes	Yes	Yes	Yes
Triage is based on	◦ Symptoms ◦ Episode of possible exposure ◦ Lifestyle risk (healthcare provider, travel history)	◦ Symptoms Episode of possible exposure ◦ Lifestyle risk (risk at workplace, travel history) ◦ Virus prevalence locally	◦ Symptoms ◦ Episode of possible exposure	◦ Symptoms ◦ Episode of possible exposure ◦ Lifestyle risk (travel history)
How often to triage	Before treatment During stimulation	Before every clinic visit	Before treatment Before every clinic visit	Before every clinic visit
Advocate COVID-19 testing	Yes	Refer to authoritative sources	Yes	Refer to local public health services
COVID-19 testing policy	Selective (if symptomatic or high-risk self-assessment)	Unclear (refer to authoritative sources, such as the Centers for Disease Control)	One routine test just before starting treatment and consider repeat before a procedure and selective (if symptomatic or high-risk self-assessment)	Selective (refer to local public health services)
Decision to cancel is based on	‘Typical’ self-reported symptoms or Positive testing	Refer to authoritative sources	Positive testing or self-reported symptoms (if no time to test)	Positive testing
If Covid-19 test is negative	Continue with treatment	Refer to authoritative sources	Continue with treatment	Continue with treatment (depending on individual assessment)
Temperature checks in clinic	No	Optional	No	Optional